GILUPI participates in Consortium “European Liquid Biopsies Academy” – ELBA
GILUPI participates in Consortium “European Liquid Biopsies Academy” – ELBA
(firmenpresse) - Blood of cancer patients contains different types of cancer-derived materials that are susceptible to detailed analysis of tumor disease: intact circulating tumor cells (CTCs), cell-free circulating tumor DNA, tumor educated platelets and extracellular vesicles. Different techniques can isolate those biomarkers and are used as diagnostic and monitoring tools for cancer treatment. These blood-based tests (also called liquid biopsy) are a sensitive and less invasive alternative or complementary approach to tissue biopsies.
The research program and educational curriculum of the European Liquid Biopsy Academy - ELBA[1], a MSCA ITN funded project (GA 765492), educates 15 early stage researchers in a range of applications and disease areas surrounding liquid biopsy. For this purpose, different companies perform trainings on state-of-the-art technologies and tools, diagnostic test development and further topics.
As part of the educational program, GILUPI, together with other companies has successfully organized the first training workshop for liquid biopsy. During this training the students got familiar with the GILUPI CellCollector® for the isolation of CTCs and were trained in using this innovative technology to analyze CTCs.
Christian Jurinke, CEO of GILUPI commented: We are proud to participate in this educational workshop and to support the ELBA organization in their goal to promote innovative medical and diagnostic applications in an international and cooperative setting.
[1] http://elba.uni-plovdiv.bg/
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
About GILUPI GmbH
GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the in vivo isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.
Individual oncological targeted therapies become increasingly important in personalized medicine. The identification of the right drug for the individual patient is todays challenge in clinical practice. To address this medical need, the GILUPI CellCollector® is used to enrich rare cells by immuno-capture directly in the patient's bloodstream. This methodology has proven to yield highest cell numbers and patient positivity rates in various cancer types. Applying diagnostic analyses ranging from immunostaining, DNA- and RNA-based methods, isolated cells can be characterized and/or analyzed down to a molecular level.
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide that is CE approved.
For further information visit www.gilupi.com
Datum: 10.01.2019 - 12:56 Uhr
Sprache: Deutsch
News-ID 586121
Anzahl Zeichen: 1665
contact information:
Contact person: Christian Jurinke
Town:
Potsdam
Phone: +49 331-5818478-2
Kategorie:
Medical Devices
Typ of Press Release: Cooperation
type of sending: send
Date of sending: 10.01.2019
Diese Pressemitteilung wurde bisher 295 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"GILUPI participates in Consortium “European Liquid Biopsies Academy” – ELBA "
steht unter der journalistisch-redaktionellen Verantwortung von
GILUPI GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
